We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (305)
- Scheduling (national classification system) (160)
- Advertising (25)
- Safety monitoring and information (23)
- COVID-19 (11)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Clinical trials (4)
- Compliance and enforcement (4)
- Shortages and supply disruptions (3)
- Legislation (2)
- Breast implant hub (1)
- Cosmetics (1)
- Import and export (1)
- Manufacturing (1)
- Prescription opioids hub (1)
Search
574 result(s) found, displaying 351 to 375
-
Scheduling decisions (final)Poisons Standard amendments to hydroxychloroquine to ensure continued availability during the COVID-19 pandemic
-
Scheduling decisions (final)Amendments in relation to hydroxychloroquine and salbutamol
-
TGA laboratory testing reportsUpdates have been made to the previously published report related to the testing of HPV vaccines available in Australia
-
Meeting statementsThe Advisory Committee on Biologicals (ACB) is a statutory advisory committee established by the Therapeutic Goods Regulations 1990
-
Meeting statementsThe Advisory Committee on Biologicals (ACB) is a statutory advisory committee established by the Therapeutic Goods Regulations 1990.
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 5 March 2020
-
Scheduling decisions (final)Final decision in relation to risankizumab
-
Scheduling decisions (final)Recommendations for the scheduling of New Chemical Entities for inclusion in the Poisons Standard
-
TGA laboratory testing reportsThe TGA Laboratories has published a detailed report related to the testing of measles vaccines available in Australia
-
Corporate reportsRegulatory Impact Self-Assessment Report
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 27 November 2019
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 26 July 2019
-
Corporate reportsThe TGA has conducted a safety review on coumarin in topical listed medicines
-
Corporate reportsOn Monday, 2 December 2019, a TGA Progress Report to the Senate Mesh Inquiry was tabled in the Senate
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Scheduling decisions (final)Delegate-only final decision and reason for New Chemical Entities (NCE) - 1 December 2019 implementation date
-
Scheduling decisions (final)Final decisions to amend the Poisons Standard for substances referred to ACMS #27, ACCS #25, Joint ACMS-ACCS #22 (June 2019) and delegate-only decisions.
-
Corporate reportsFurther comments received on the consultation
-
Meeting statementsCommunique from the fourth meeting of the TGACC
-
Corporate reportsOverview of therapeutic goods advertising complaints handling and compliance for the year 2018-19
-
Meeting statementsAustralian Influenza Vaccine Committee (AIVC) recommendations
-
TGA laboratory testing reportsReport on TGA Laboratories review of the surface of 52 different models of breast implants and tissue expanders
-
Scheduling decisions (final)Delegate-only final decisions and reasons for New Chemical Entities (NCEs) - 1 October 2019 implementation date
-
Meeting statementsThe TGA hosted a stakeholder forum in Melbourne on 10 October 2018
-
Corporate reportsThe TGA thanks respondents who provided submissions